These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

86 related items for PubMed ID: 3383431

  • 21. Intraperitoneal deferoxamine therapy for aluminum intoxication in a child undergoing continuous ambulatory peritoneal dialysis.
    Andreoli SP, Dunn D, DeMyer W, Sherrard DJ, Bergstein JM.
    J Pediatr; 1985 Nov; 107(5):760-3. PubMed ID: 3932629
    [No Abstract] [Full Text] [Related]

  • 22. Deferoxamine-enhanced fecal losses of aluminum and iron in a patient undergoing continuous ambulatory peritoneal dialysis.
    McCarthy JT, Kurtz SB, Mussman GV.
    Am J Med; 1987 Feb; 82(2):367-70. PubMed ID: 3812538
    [Abstract] [Full Text] [Related]

  • 23. Antioxidant status of elderly chronic renal patients treated by continuous ambulatory peritoneal dialysis.
    Bonnefont-Rousselot D, Jaudon MC, Issad B, Cacoub P, Congy F, Jardel C, Delattre J, Jacobs C.
    Nephrol Dial Transplant; 1997 Jul; 12(7):1399-405. PubMed ID: 9249776
    [Abstract] [Full Text] [Related]

  • 24. Factors influencing serum aluminum in CAPD patients.
    Montenegro J, Aguirre R, Saracho R, Moina I, Martínez I.
    Clin Nephrol; 1998 Aug; 50(2):77-83. PubMed ID: 9725777
    [Abstract] [Full Text] [Related]

  • 25. Changes of metal concentrations in blood and peritoneal dialysate during long-term desferrioxamine B therapy.
    Romero RA, Salgado O, Elejalde LE, Rodríguez-Iturbe B, Tahán JE.
    Transplant Proc; 1996 Dec; 28(6):3385-7. PubMed ID: 8962321
    [No Abstract] [Full Text] [Related]

  • 26. Aluminum concentrations in serum, dialysate, urine and bone among patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
    Joffe P, Olsen F, Heaf JG, Gammelgaard B, Pödenphant J.
    Clin Nephrol; 1989 Sep; 32(3):133-8. PubMed ID: 2791364
    [Abstract] [Full Text] [Related]

  • 27. Atenolol pharmacokinetics in patients on continuous ambulatory peritoneal dialysis.
    Salahudeen AK, Wilkinson R, McAinsh J, Bateman DN.
    Br J Clin Pharmacol; 1984 Sep; 18(3):457-60. PubMed ID: 6487486
    [Abstract] [Full Text] [Related]

  • 28. Serum ferritin and bone marrow iron in patients undergoing continuous ambulatory peritoneal dialysis.
    Blumberg AB, Marti HR, Graber CG.
    JAMA; 1984 Sep; 250(24):3317-9. PubMed ID: 6645029
    [Abstract] [Full Text] [Related]

  • 29. Single-dose pharmacokinetics of cefpirome in patients receiving hemodialysis and in patients treated by continuous ambulatory peritoneal dialysis.
    Veys N, Lameire N, Malerczyk V, Lehr KH, Rosenkranz B, Ringoir S.
    Clin Pharmacol Ther; 1993 Oct; 54(4):395-401. PubMed ID: 8222482
    [Abstract] [Full Text] [Related]

  • 30. Prevention and treatment of aluminum intoxication in chronic renal failure.
    Simon P, Allain P, Ang KS, Cam G, Mauras Y.
    Adv Nephrol Necker Hosp; 1985 Oct; 14():439-78. PubMed ID: 3919543
    [No Abstract] [Full Text] [Related]

  • 31. Deferoxamine and aluminum removal.
    Swartz RD.
    Am J Kidney Dis; 1985 Nov; 6(5):358-64. PubMed ID: 3904429
    [No Abstract] [Full Text] [Related]

  • 32. Pharmacokinetics of intravenous and intraperitoneal cefotaxime in chronic ambulatory peritoneal dialysis.
    Albin HC, Demotes-Mainard FM, Bouchet JL, Vincon GA, Martin-Dupont C.
    Clin Pharmacol Ther; 1985 Sep; 38(3):285-9. PubMed ID: 4028623
    [Abstract] [Full Text] [Related]

  • 33. Quantification of desferrioxamine, ferrioxamine and aluminoxamine by post-column derivatization high-performance liquid chromatography. Non-linear calibration resulting from second-order reaction kinetics.
    Kraemer HJ, Breithaupt H.
    J Chromatogr B Biomed Sci Appl; 1998 Jun 12; 710(1-2):191-204. PubMed ID: 9686887
    [Abstract] [Full Text] [Related]

  • 34. Aluminum removal by peritoneal dialysis: intravenous vs. intraperitoneal deferoxamine.
    Hercz G, Salusky IB, Norris KC, Fine RN, Coburn JW.
    Kidney Int; 1986 Dec 12; 30(6):944-8. PubMed ID: 3820944
    [Abstract] [Full Text] [Related]

  • 35. [Chronic aluminum poisoning in continuous ambulatory peritoneal dialysis: treatment with deferoxamine].
    Passlick J, Wilhelm M, Busch T, Grabensee B, Ohnesorge FK.
    Dtsch Med Wochenschr; 1989 Feb 17; 114(7):253-7. PubMed ID: 2917487
    [Abstract] [Full Text] [Related]

  • 36. Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
    Bene C, Manzler A, Bene D, Kranias G.
    Clin Nephrol; 1989 Jan 17; 31(1):45-8. PubMed ID: 2783668
    [Abstract] [Full Text] [Related]

  • 37. Continuous ambulatory peritoneal dialysis: three years' experience.
    Ramos JM, Gokal R, Siamopolous K, Ward MK, Wilkinson R, Kerr DN.
    Q J Med; 1983 Jan 17; 52(206):165-86. PubMed ID: 6611839
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of intramuscular and intraperitoneal deferoxamine for aluminum chelation.
    Molitoris BA, Alfrey PS, Miller NL, Hasbargen JA, Kaehney WD, Alfrey AC, Smith BJ.
    Kidney Int; 1987 Apr 17; 31(4):986-91. PubMed ID: 3586503
    [Abstract] [Full Text] [Related]

  • 39. Vitamin A losses during continuous ambulatory peritoneal dialysis.
    Vahlquist A, Berne B, Danielson BG, Grefberg N, Berne C.
    Nephron; 1985 Apr 17; 41(2):179-83. PubMed ID: 4047276
    [Abstract] [Full Text] [Related]

  • 40. Desferrioxamine in the treatment of aluminum overload.
    Ackrill P, Day JP.
    Clin Nephrol; 1985 Apr 17; 24 Suppl 1():S94-7. PubMed ID: 3842106
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.